Haldol (Page 5 of 5)

Switchover Procedure

An oral form should supplant the injectable as soon as practicable. In the absence of bioavailability studies establishing bioequivalence between these two dosage forms the following guidelines for dosage are suggested. For an initial approximation of the total daily dose required, the parenteral dose administered in the preceding 24 hours may be used. Since this dose is only an initial estimate, it is recommended that careful monitoring of clinical signs and symptoms, including clinical efficacy, sedation, and adverse effects, be carried out periodically for the first several days following the initiation of switchover. In this way, dosage adjustments, either upward or downward, can be quickly accomplished. Depending on the patient’s clinical status, the first oral dose should be given within 12–24 hours following the last parenteral dose.

INSTRUCTIONS FOR OPENING AMPULE

Step 1
1.
Medication often rests in the top part of the ampule. Before breaking the ampule, lightly tap the top of the ampule with your finger until all fluid moves to the bottom portion of the ampule. The ampule has a colored ring(s) and colored point which aids in the placement of fingers while breaking the ampule.

Step 1

Step 2
2.
Hold the ampule between thumb and index finger with the colored point facing you.

Step 2

Step 3
3.
Position the index finger of the other hand to support the neck of the ampule. Position the thumb so that it covers the colored point and is parallel to the colored ring(s).

Step 3

Step 4
4.
Keeping the thumb on the colored point and with the index fingers close together, apply firm pressure on the colored point in the direction of the arrow to snap the ampule open.

Step 4

HOW SUPPLIED

HALDOL brand of haloperidol Injection (For Immediate Release) 5 mg per mL (as the lactate) – NDC 50458-255-01, units of 10 × 1 mL ampules.

Store HALDOL (haloperidol) Injection at controlled room temperature (15°–30°C, 59°–86°F). Protect from light. Do not freeze.

Keep out of reach of children.

Product of Belgium

Manufactured for:
Janssen Pharmaceuticals, Inc.
Titusville, NJ 08560

Revised November 2020

© 2005 Janssen Pharmaceuticals Companies

PRINCIPAL DISPLAY PANEL- 5 mg ampule box

NSN 6505-00-268-8530
NDC 50458-255-01

Usual Dosage
For dosage and
other prescribing
information, see
accompanying
product literature.

Dispense in a light-
resistant container
as defined in the
official compendium.

Store at controlled
room temperature
(15°-30°C, 59°-86°F).
Protect from light.
Do not freeze.

Haldol®
BRAND OF

HALOPERIDOL
INJECTION
For Itramuscular Use
For Immediate Release

5 mg per mL

10 x 1-mL
STERILE AMPULES

Rx only.

Each mL contains:
Haloperidol 5 mg
(as the lactate) and
lactic acid for pH
adjustment to 3.0-3.6

For Intramuscular Use

Product of Belgium
Mfg by: GlaxoSmithKline
Manufacturing S.p.A.
Parma, Italy

Mfg for: Janssen
Pharmaceuticals, Inc.Titusville, NJ 08560

62000000040377

© 2005 Janssen

Janssen

Principal Display Panel- 5 mg vial box
(click image for full-size original)
HALDOL haloperidol injection
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:50458-255
Route of Administration INTRAMUSCULAR DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Haloperidol lactate (Haloperidol) Haloperidol 5 mg in 1 mL
Inactive Ingredients
Ingredient Name Strength
LACTIC ACID, UNSPECIFIED FORM
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:50458-255-01 10 AMPULE in 1 BOX contains a AMPULE
1 1 mL in 1 AMPULE This package is contained within the BOX (50458-255-01)
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA015923 05/18/1971 08/02/2050
Labeler — Janssen Pharmaceuticals, Inc. (063137772)
Establishment
Name Address ID/FEI Operations
Janssen Pharmaceutica N.V. 400345889 API MANUFACTURE (50458-255)
Establishment
Name Address ID/FEI Operations
GlaxoSmithKline 338471078 MANUFACTURE (50458-255), ANALYSIS (50458-255)

Revised: 08/2021 Janssen Pharmaceuticals, Inc.

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2022. All Rights Reserved.